Table 2.
Treatment discriminated by stage
| DCIS (n = 1) | I (n = 4) | II (n = 21) | III (n = 19) | IV (n = 3) | Total (n = 48) | |
|---|---|---|---|---|---|---|
| Neoadjuvant chemotherapy | 3 | 11 | 14 (29 %) | |||
| Surgery | 41 (85 %) | |||||
| None | 1a | 3 | 4 (8 %) | |||
| BCT: LAND | 2 | 7 | 9 (19 %) | |||
| MRM | 1 | 2 | 12 | 16 | 31 (65 %) | |
| BM | 1 | 1 (2 %) | ||||
| Refused | 1 | 2 | 3 (6 %) | |||
| Adjuvant chemotherapy | 2 | 12 | 4 | 1 | 19 (40 %) | |
| Refused chemotherapy | 1 | 1 | 2 (4 %) | |||
| Hormonal therapy | 23 (48 %) | |||||
| Alone | 2 | 3 | 3 | 2 | 10 (21 %) | |
| With chemotherapy | 8 | 5 | 13 (21 %) | |||
| Her-2 directed | 1 | 1 (2 %) | ||||
| Radiation | 2 | 6 | 6 | 14 (29 %) | ||
| Refused radiation | 1 | 3 | 1 | 5 (10 %) | ||
| Relapse/PD | 1 | 9 | 13 | 2 | 25 (52 %) | |
| Chemotherapy | 4 | 1 | 5 (10 %) | |||
| XRT | 4 | 4 | 8 (17 %) | |||
| Refused | 1 | 1 | 2 (4 %) | |||
| Hormonal | 2 | 2 | 4 (8 %) | |||
| Her-2/neu directed | 1 | 1 (2 %) |
BCT Breast conservation therapy, MRM modified radical mastectomy, PD progressive disease, XRT radiation
aPD during treatment